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Selective inhibition of CTCF binding by iAs directs TET-mediated
reprogramming of 5-hydroxymethylation patterns in iAs-transformed cells
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A B S T R A C T
Methylation at cytosine (5mC) is a fundamental epigenetic DNA modification recently associated with iAs-
mediated carcinogenesis. In contrast, the role of 5-hydroxymethylcytosine (5hmC), the oxidation product of 5mC
in iAs-mediated carcinogenesis is unknown. Here we assess the hydroxymethylome in iAs-transformed cells,
showing that dynamic modulation of hydroxymethylated DNA is associated with specific transcriptional net-
works. Moreover, this pathologic iAs-mediated carcinogenesis is characterized by a shift toward a higher hy-
droxymethylation pattern genome-wide. At specific promoters, hydroxymethylation correlated with increased
gene expression. Furthermore, this increase in hydroxymethylation occurs concurrently with an upregulation of
ten-eleven translocation (TET) enzymes that oxidize 5-methylcytosine (5mC) in DNA. To gain an understanding
into how iAs might impact TET expression, we found that iAs inhibits the binding of CTCF at the proximal, weak
CTCF binding sites of the TET1 and TET2 gene promoters and enhances CTCF binding at the stronger distal
binding site. Further analyses suggest that this distal site acts as an enhancer, thus high CTCF occupancy at the
enhancer region of TET1 and TET2 possibly drives their high expression in iAs-transformed cells. These results
have major implications in understanding the impact of differential CTCF binding, genome architecture and its
consequences in iAs-mediated pathogenesis.
1. Introduction
Each year millions of people worldwide are exposed to the ubiqui-
tous carcinogen, inorganic arsenic (iAs) (IARC, 2004; Salnikow and
Zhitkovich, 2008; Cheng et al., 2012; IARC, 2012). This exposure oc-
curs mainly through drinking water and food, and can result in acute
toxicity and malignant transformation, among other consequences. The
severity of these consequences is related to the dose and duration of
exposure to this toxicant (Huang et al., 2004; Ren et al., 2011). Many
mechanisms have been implicated in the altered gene expression in iAs-
induced toxicity and pathogenesis, including oxidative stress. An
equally important mechanism – changes to the epigenome – is also
known to alter gene expression in iAs-induced pathogenesis (Bird,
2002; Feng et al., 2010).
Epigenetic mechanisms include changes in DNA methylation, post-
translational modification of histones, histone variants and microRNAs.
Disruption of these epigenetic processes can lead to altered gene
function and malignant transformation. Several recent studies showed
that the iAs exposure can alter these epigenetic marks (Rea et al., 2016;
Eckstein et al., 2017a; Rea et al., 2017). These changes to the epi-
genome drive specific gene expression patterns relevant to disease pa-
thogenesis (Arita and Costa, 2009; Treas et al., 2012; Miao et al., 2015;
Chen et al., 2016). Among these epigenetic marks, DNA methylation,
the addition of a methyl group to the 5′ carbon of cytosine residues, is
considered the most stable (Okano et al., 1999). DNA methylation
within a promoter region is repressive for gene expression, while DNA
methylation within a gene body is generally thought to increase gene
expression, though it may also play a role alternative splicing (Herman
and Baylin, 2003; Ball et al., 2009; Jjingo et al., 2012; Jones, 2012;
Nestor et al., 2012; Rea et al., 2017). With respect to tumorigenesis,
changes in methylation levels have been linked to differential expres-
sion of genes, that lead cells through epithelial-to mesenchymal tran-
sition (EMT) and into a cancerous state (Jones and Baylin, 2002;
Berman et al., 2012; Hon et al., 2012; Jones, 2012; Ashktorab et al.,
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2014).
Until recently, DNA methylation was thought to be permanent and
removed only if there was a mistake in the replication process, or a
malfunction of the DNA methyltransferases – enzymes that write or
maintain this mark – or through passive demethylation (Mayer et al.,
2000; Guo et al., 2014). However, recent studies found that this process
is dynamic with demethylases excising the modified cytosine residue
(Cortellino et al., 2011; Song and He, 2012). In plants, multiple families
of DNA glycosylases (DME and ROS) are responsible for the removal of
5-methylCytosine (5mC) followed by the base excision repair pathway
replacing the cytosine (Kinoshita et al., 2004; Xiao et al., 2006; Feng
et al., 2010; Rea et al., 2012). In mammals, active demethylation is a
complex process involving several modifications of the 5mC with its
eventual removal by thymine DNA glycosylase (TDG) (He et al., 2011;
Kohli and Zhang, 2013). First, a TET (ten-eleven translocation me-
thylcytosine dioxygenase) family member oxidizes 5mC converting it to
5-hydroxymethylcytosine (5hmC) (He et al., 2011; Zhang et al., 2013;
Chen and Wu, 2016). This newly modified cytosine, now considered the
sixth base, is a stable intermediate, playing a role in gene regulation
(Bachman et al., 2014). For DNA demethylation, 5hmC is further
modified to 5-formylcytosine and 5-carboxylcytosine, which then al-
lows for its removal by the mammalian TDGs through the base excision
repair pathway. And lastly, an unmodified cytosine is added to the DNA
sequence (He et al., 2011; Ito et al., 2011; Zhang et al., 2013; Hu et al.,
2014).
We previously reported that chronic low-dose iAs exposure leads to
iAs-induced cellular transformation through genome-wide loci specific
reprogramming of DNA methylation (Rea et al., 2017), that drive spe-
cific gene expression patterns. Here we report that during iAs-induced
cellular transformation, 5hmC levels increase globally, as well as at
specific loci. Many of the genes and pathways affected by the differ-
ential DNA methylation as well as differential hydroxymethylation
between NT and iAs-T cells, are involved in the cellular adhesion, cell
communication and neurogenesis. We attribute this increase in the
global 5hmC levels to the increased expression of the TETs, which ap-
pears to be driven through increased binding of CTCF to the distal
promoter. Our data therefore presents a platform to begin to tease the
differential binding of ‘master regulators’ such as CTCF to drive specific
epigenetic patterns critical in disease pathogenesis.
2. Experimental procedures
2.1. Cell growth conditions and transformation with sodium arsenite
BEAS-2B were grown in Dulbecco's modified Eagle medium (Sigma-
Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine
serum (Sigma-Aldrich), 1% MEM non-essential amino acids (Sigma-
Aldrich) and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were
grown to ~80% confluency in a humidified chamber at 37 °C, 5% CO2
prior to use. Cells were transformed with low-dose Sodium Arsenite
(0.5 μM-Sigma-Aldrich) for 8 weeks and phenotypic changes were ob-
served indicating epithelial-to-mesenchymal transformation. This
transformation was confirmed at both transcript and protein levels of
known EMT markers (Riedmann et al., 2015; Rea et al., 2016).
2.2. qRT-PCR
RNA was isolated from 1 × 107 BEAS-2B cell with RNeasy MiniKit
(Qiagen). 1 μg of RNA was used in a reverse transcriptase reaction with
iScript Reverse Transcriptase (Bio-Rad #1708891) to prepare cDNA.
25 ng of the cDNA was used in each of the qRT-PCR reactions. The
reaction protocol was as follows: 1) 94 °C 5 min; 2) 94 °C 30 s; 3)
55–63 °C (dependent on primer pair) 30 s; 4) 72 °C 45 s; 5) repeat steps
2–4 for 40 cycles; 6) 72 °C 10 min. Primers for the housekeeping gene
(GAPDH) and primers used for genes with differential 5hmC were
created for this study using PrimerBank (Supplemental Table 5)
(Spandidos et al., 2008, 2010).
2.3. Gene ontology
Genes with 20 or more reads of differential 5hmC reads in the
promoter regions were subjected to a gene ontology annotation using
the Consensus PathDatabase (CPDB-Max Plank Institute; http://
consensuspathdb.org) using terms or pathways that had at least 10
genes and p-values < 0.05 (Kamburov et al., 2011, 2013). Resulting
− log10 (p-value) are graphed.
2.4. Reduced Representation Hydroxymethylcytosine Profiling (RRHP)
library preparation
Genomic DNA was fragmented overnight at 37 °C with a hydro-
xymethyl-insensitive enzyme, MspI, and purified using the DNA Clean
and Concentrator kit (Zymo Research). Modified Illumina TruSeq P5
and P7 adapters containing 5′-CG overhangs were ligated onto the di-
gested DNA using T4 DNA ligase (2 h at 16 °C). Libraries were then
strand extended at 72 °C with Taq DNA Polymerase. The adapters were
designed to regenerate the 5′-CCGG site at the P5 junction while the P7
adapter generates a 5′-TCGG junction, making it insensitive to MspI
digestion. Adapterized libraries were treated with β-glucosyltransferase
to label 5-hmC modifications and purified using the DNA Clean and
Concentrator kit. The glucosylated libraries were then subjected to an
overnight MspI digestion at 37 °C, cutting any fragments not containing
a glucosyl-5hmC site at the P5 CCGG junction. After incubation, the
libraries were size-selected from 100 bp to 500 bp and purified using
the ZymoClean Gel DNA Recovery Kit (Zymo Research). The fragments
were amplified using OneTaq 2× Master Mix (NEB), and the PCR
conditions include an initial denaturation of 94 °C for 30 s followed by
12 cycles of 94 °C for 30 s, 58 °C for 30 s, and 68 °C for 1 min.
Fragments containing 5-hmC were positively selected during PCR am-
plification with adapter-specific indexing primers whereas fragments
lacking glucosylated-5-hmC at the P5 junction were cleaved and,
therefore, not amplified by PCR. Amplified libraries were purified using
the DNA Clean and Concentrator kit, and multiplexed using equal vo-
lume of the libraries. Integrated DNA Technologies synthesized all
adapters and primers used in these studies. RRHP analysis was per-
formed with 2 biological replicates. To confidently identify 5hmC-en-
riched regions and sites, we used algorithm based on local likelihood
smoothing (BSmooth) to identify consensus 5hmC regions and sites for
each NT and iAs-T cells. We have previously used this method suc-
cessfully to identify differentially methylated regions especially be-
tween groups with low sequencing coverage (Rea et al., 2016).
2.5. Bioinformatics processing and statistical analyses
Sequence reads from RRHP libraries were first processed to trim off
the low-quality bases and the P7CG adapter at the 3′ end of the reads.
Reads were then aligned to the reference genome (GRCh37/hg19) using
the bowtie1 default parameters and –best. Aligned reads with the MspI
tag (CCGG) were counted. The correlation analysis between different
RRHP libraries was performed by comparing the presence of the tagged
reads at each profiled MspI site, and Pearson's coefficient was calcu-
lated accordingly.
2.6. Chromatin immunoprecipitation
ChIP analyses were performed as previously described (Rea et al.,
2017) using 25 μg of crosslinked chromatin and 2 μg of specific anti-
bodies for the immunoprecipitations, which are listed in Supplemental
Table 4. 2 μL of eluate was used for qPCR (described above) to de-
termine the CTCF occupancy differences and the histone modifications
in the TET family promoter regions. Primers used in ChIP analyses are
listed in Supplemental Table 5.
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2.7. 5hmC DNA immunoprecipitation (5hme-DIP)
Genomic DNA was purified from 5 × 106 cells (BEAS-2B NT and
iAs-T) using Qiagen DNeasy Blood and Tissue Kit (Qiagen 69506) and
5hme-DIP was performed using the EpiQuik hMeDIP Kit (Epigentek P-
1038) following the manufacturer's protocol. 2 μL of eluate was used in
qRT-PCR reactions to determine changes in 5hmC occupancy at loci
showing differential 5hmC levels from RRHP. Primers used are listed in
Supplemental Table 5.
2.8. Dot blots
Purified genomic DNA from non-treated (NT) and iAs-T cells were
diluted to 50 ng/μl. 25 ng −125 ng of genomic DNA were spotted on
Positively charged Nylon Membrane (Invitrogen AM10104). These
were allowed to air dry, then DNA was UV-crosslinked to the membrane
by placing on a UV transilluminator (Biorad) for 3 min. Membranes
were blocked with 5% Milk +PBST, then incubated with the 5hmC
antibody (Abcam AB106918-1:500 dilution) overnight at 4 °C. Alkaline-
phosphate conjugated anti-rat secondary antibody was added and in-
cubated for 1 h at room temperature. After washing three times with
PBST, the blots were developed with ECF (Vistra ECF Western blotting
system, GE Health Care) following the manufacturer's protocol. The
Western bands were scanned with the GE-Typhoon FLA9500, and in-
tensities of each dot were quantified using ImageQuant (GE Health
Care).
2.9. TET hydroxylase activity assay
Total nuclear protein fraction was extracted from NT and iAs-T cells.
In details, cells were gently resuspended in hypotonic solution (20 mM
Tris-Cl, pH 7.4; 10 mM NaCl; 3 mMMgCl2) and allow to sit for 5 min on
ice. Cells were then lysed by adding NP-40 to a final concentration of
1% and vortexed. Thereafter, nuclei were pelleted by centrifugation at
4 °C for 10 min. Nuclei were then lysed with 1× RIPA buffer
(Thermofisher Scientific; Cat # 89900) for 30 min on ice and cen-
trifuged for 10 min at full speed. Supernatant was used to estimate the
protein concentration using the BCA assay. For each experiment, 20 μg
of nuclear protein extract was used to determine TET activity using the
Epigentek-Epigenase 5mC Hydroxylase TET Activity/Inhibition Assay
Kit (Colorimetric) (Epigentek #P-3086). TET activity was calculated in
two ways: 1) Specific Activity through a standard curve (expressed in
ng/min/mg – Fig. 6B) and 2) Simple Calculation (expressed in OD/min/
mg – Supplemental Fig. 5) as suggested by manufacturer.
3. Results
3.1. Increase in 5hmC in cells transformed with chronic, low-dose iAs
We previously showed using ELISA (enzyme-linked immunosorbent
Table 1
Read efficiency of RRHP.
Total number of reads Mapping efficiency Detected CpGs Average read count (coverage) Loci with> 20 reads Loci with> 50 reads
NT 38.27 × 106 63% 1.93 × 106 9 10,542 340
iAsT 58.81 × 106 68% 2.04 × 106 13 96,538 30,665
Fig. 1. Profiling analysis through RRHP reveals a global
increase in 5hmC. (A) Scatter Plot from RRHP analysis
showing an increase in global 5hmC levels in iAs-T cells. (B)
Representative Dot Blot shows global 5hmC levels in NT
BEAS-2B (NT) cells compared with cells exposed for
8 weeks with chronic, low dose iAs (iAs-T) shows higher
overall 5hmC levels in iAs-T cells (top), and methylene blue
staining for genomic DNA (bottom) for loading control. (C)
Quantification of 3 independent Dot Blots showing an in-
crease in 5hmC levels with the increasing concentrations of
genomic DNA. Shown is one biological replicate with 3
technical replicates, a second biological replicate with
technical replicates showed similar results. The * denotes
p < 0.05 and error bars represent the SEM. (For inter-
pretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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assay), that there was little or no change in global DNA methylation
between NT and iAs-T BEAS-2B cells. However, in the same studies
using high-resolution single nucleotide MiniMethyl-Seq analysis, we
showed many loci-specific hypermethylation and hypomethylation
changes. These studies suggested that the iAs-mediated DNA methyla-
tion reprogramming directed differential gene expression in iAs-trans-
formed cells, both at the transcription initiation and splicing levels (Rea
et al., 2017). DNA methylation although a more stable modification,
can be removed in mammals, through the conversion of 5mC to 5hmC
by the TET family of proteins. The 5hmC is then further modified to 5-
formylcytosine, and eventually to 5carboxycytosine, before being re-
cognized by the Base Excision Repair Pathway, removed, and replaced
with a non-modified cytosine.
Our previous studies showing both hypermethylation and hypo-
methylation at many sites, prompted us to ask whether some of the
hypomethylation sites are due to removal of the 5mC by TETs to 5-
hydroxymethylation. We therefore carried out a high-resolution RRHP
protocol followed by sequencing, to determine the regions with dif-
ferential 5hmC in time-matched NT and iAs-BEAS-2B transformed cells
(iAs-T). RRHP makes use of the unique glucosylation of 5hmC, and a
second MspI digestion; the glucosylated 5hmC can be distinguished
from 5mC at CCGG sequences (Petterson et al., 2014). After sequencing,
we obtained a library of 38.27 × 106 reads covering 1.93 × 106 unique
CpG sites for NT and 58.81 × 106 reads covering 2.04 × 106 unique
CpG sites for iAsT with average read counts of 9 and 13 per CpG, re-
spectively (Table 1). These mapped to the human genome (GRCh37/
hg19) at 63% and 68% for NT and iAsT, respectively (Table 1). A total
of 2,165,849 unique loci were found with 5hmC, which is about 0.07%
of the total genome. This value is in line with previous observations that
5hmC is relatively low in non-neural tissue humans (Globisch et al.,
2010; Ye and Li, 2014). Comparison of NT and iAs-T results showed a
high correlation between these samples (Pearson correlation
r = 0.9771), with some strong outliers, in the iAs-T sample (Fig. 1A).
RRHP profiling is not an absolute quantification of 5hmC, but it is a
positive read assay, so that increased 5hmC levels at a specific locus
returns higher read numbers. Thus based on this assertion, the total
global number of reads in iAs-T cells was ~20 million more than in NT
cells, indicating an increase in hydroxymethylation in these cells. This
increase in 5hmC reads is interesting as the distribution is not limited to
any specific chromosome or region, but is well distributed across the
genome. Further analysis showed an increase of 5-hydroxymethylation
at 65.77% of loci, while 24.93% of loci showed decreased 5hmC levels
in the iAs-T compared to NT cells. The remaining 9% of CCGG sites
showed no difference in 5hmC levels (Supplemental Table 1). We
confirmed this global increase in 5hmC through Dot Blot analysis using
an antibody directed toward 5hmC (Fig. 1B). Genomic DNA isolated
from both NT and iAs-T cells was titrated linearly by blotting 25 ng to
125 ng and probed with antibody specific for 5hmC. The staining was
quantified and results show that at 50 ng DNA concentration, a 10-fold
in 5hmC was seen in iAs-T compared to NT, while at 75 ng a 4-fold
increase was seen (Fig. 1C). These results validate the global increase in
5hmC levels measured through with RRHP.
To begin to understand the functional impact of these differential
hydroxymethylation patterns, we analyzed the genes with changes in
5hmC pattern. We performed a gene ontology (GO) analysis using the
Consensus PathDatabase (CPDB-Max Plank Institute) (Kamburov et al.,
2011, 2013), and the most enriched GO Biological Process and Mole-
cular function for these genes are cell communication, cell adhesion,
neurogenesis, transcription factor activity and metal ion binding
(Fig. 2A and B). These same GO terms were associated with genes with
altered DNA methylation patterns from our previous studies (Rea et al.,
2017). We next carried out the Kyoto encyclopedia of genes and gen-
omes (KEGG) pathway enrichment analysis to identify the enriched
metabolic or signaling pathways in which these genes are involved.
This analysis revealed cell communication pathways, integrin cell ad-
hesion, focal adhesion and multiple cellular adhesion pathways as the
most enriched pathways (Fig. 2C). Interestingly, many of these adhe-
sion genes had lower 5-hydroxymethylation and were down-regulated
in gene expression (Supplemental Table 2).
We and others have shown that DNA methylation occurs not only at
promoter regions but also at other regulatory regions (Khalid et al.,
2014; Kubo et al., 2015; Rea et al., 2017). We therefore asked if these
changes in 5hmC occur at other functional genomic regions as well. For
these analyses, we used a stringent read number of> 20 (Table 1) al-
lowing for a deeper assessment of the 5hmC distribution in the genome
(Petterson et al., 2014; Grosser et al., 2015; Tekpli et al., 2016). We
observed a similar differential of 5hmC distribution at functional
genomic regions - 46% differential hypo- and hyper-5hydro-
xymethylation within introns, 11% within exons, 36% in intergenic
regions, and about 7% at the promoters (Fig. 3A and B). While this
distribution of hypo- and hyper-hydroxymethylation is similar, there
were more loci (9.5× more reads) for hyper-hydroxymethylation
compared to hypo-hydroxymethylation in iAs-T compared to NT cells
(96,538 vs. 10,542 - Table 1), again confirming increased hydro-
xymethylation in iAs-T cells. If we increase the stringency to> 50 reads
we again see a similar distribution in functional genomic regions
(Supplemental Fig. 1), however 30,665 loci with more reads indicating
Fig. 2. Enrichment analysis of genes with differential 5hmC. Gene Ontology Analysis of
global 5hmC changes show alterations to genes involved in cellular adhesion, cellular
communication, transcription factor activity, and neural cell growth for (A) Biological
Processes (B) Molecular Function (C) Pathway-based Sets.
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increased 5hmC and 340 loci with less reads or decreased 5hmC
(Table 1).
3.2. Differential promoter 5hmC levels correlate with gene expression
changes
Changes in promoter 5mC levels correlate with changes in gene
expression (Eckstein et al., 2017b; Rea et al., 2017). This is an inverse
correlation relationship - increased promoter 5mC correlates with de-
crease gene expression while decreased promoter 5mC levels correlates
with increase gene expression. Since hydroxylation of 5mC to 5hmC is
the first step in the active DNA demethylation process, we next asked if
the observed changes in promoter 5hmC levels correlate to changes in
gene expression – if increased 5hmC correlates to increased gene ex-
pression and vice versa. First, we analyzed and validated the change in
occupancy of 5hmC at 5 different promoters with RRPH identified in-
creased 5hmC in iAs-T cells compared to NT cells (Fig. 4A). We used
hydroxymethylated DNA immunoprecipitation (5hme-DIP) followed by
quantitative real-time PCR (qRT-PCR) for these analyses. In detail,
genomic DNA was sonicated, and then immunoprecipitated with 5hmC-
specific antibody. Resulting DNA was purified and subjected qRT-PCR
to determine the relative occupancy of 5hmC at specific gene loci.
Hyper-5hmC was confirmed at the promoters of FGF4, PTPN5, SNAIL,
SOX10, and TET3 (Fig. 4A). We then asked whether this change in
5hmC correlated with increased gene expression. Using quantitative
RT-PCR, we observed an increase in gene expression in iAs-T compared
to NT for all of the 5 hyper-hydroxymethylated promoters, cells
(Fig. 4B).
Next, we also validated the observed decreased 5hmC at 6 different
promoter loci - ADAR, DNMT3B, ETS2, GNAI2, TUBB, and PTPN1
(Fig. 4C). Many of these with decreased 5hmC levels in the promoter
are involved with cellular adhesion. Here too, the 6 promoters with
reduced hydroxymethylation in iAs-T compared to NT cells, showed a
decrease in gene expression levels (Fig. 4D). These results are in line
with other studies showing a positive correlation of hydroxymethyla-
tion levels with levels of gene expression (Colquitt et al., 2013; Tsai
et al., 2014; Skvortsova et al., 2017). Indeed, other genes that had
differential promoter hydroxymethylation from RRHP (though we were
not able to amplify products from 5hme-DIP) also showed correlating
changes in gene expression levels. MMP2, FOXC2, BAG2 and UBB all
show increased gene expression correlating with the hyper-hydro-
xymethylation levels observed from RRHP, while PRKACA, and OLFM1
show decreased expression levels correlating with decreased promoter
5hmC levels observed in the RRHP data (Supplemental Fig. 2). These
genes used for validation were chosen based on the fact that they
showed both high differential 5hmC and gene expression as seen in our
microarray dataset (GSE90211).
3.3. Overlap of 5mC (MethylMIni-Seq) and 5hmC (RRHP)
Bisulfite sequencing is a widely used technique to map 5mC and
5hmC sites. However, neither bisulfite-treated 5mC nor 5hmC can un-
dergo the C → T transitions, rendering this method unable to distin-
guish between 5mC and 5hmC sites (Huang et al., 2010; Yu et al., 2012;
Petterson et al., 2014). The additional step of glucosylation of 5hmC in
the RRPH technique, gives it the ability to distinguish between 5mC and
5hmCs. Since we had shown previously using MethylMini-Seq that iAs-
mediated transformation resulted in extensive DNA methylation re-
programming (Rea et al., 2017), we asked if some of those previously
identified 5mC sites were indeed 5hmC sites (Booth et al., 2012; Chen
Fig. 3. Distribution of differential 5hmC in functional
genomic regions with stringent read counts of> 20.
Number of loci with 20+ reads, are low within promoter
regions and high in the Introns. (A) Number of loci that
show increased 5hmC levels in iAs-T. (B) Number of loci
that show decreased 5hmC levels in iAs-T. Increased 5hmC
loci total 96,538, while only 10,542 loci show decreased
5hmC levels. Even though there is a difference in loci, the
relative distribution between promoter, intron, exon, and
intergenic regions is very similar.
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et al., 2013; Petterson et al., 2014). We carried out an overlap of our
RRPH data with the methyl-seq data and found that 7532 loci showed
both significant 5mC changes as well as differential 5hmC levels
(Supplemental Table 3). The distribution of these changes was as fol-
lows: 46.6% in gene bodies (37.7% in intron, and 8.91% exon), 43.6%
in intergenic regions and 9.8% at promoters (Fig. 5). This distribution
of changed sites is similar to the overall changes seen in 5hmC levels
(Fig. 3). We categorize the overlapping sites into six categories: 1)
Hypermethylation and increased 5hmC - could indicate sites of 5hmC,
2) Hypermethylation and decreased 5hmC - could indicate sites of 5mC,
3) Hypermethylation and no change in 5hmC - could indicate sites of
5mC, 4)Hypomethylation and increased 5hmC - could indicate 5hmC
sites, 5) Hypomethylation and decreased 5hmC - could indicate the
possible removal of the 5mC completely in the treated cells or 6) Hy-
pomethylation and no change in 5hmC - could indicate loci where 5mC
is removed (Supplemental Table 3 Browser tracks for representative
four genes (GDF2, CLN5, CHST13, and DISP2) in the UCSC genome
browser provide examples of categories 1, 2, 4, and 5 (Supplemental
Fig. 3). Gene ontology analysis showed similar over-represented func-
tional groups - cell adhesion, cell communication, cell signaling, neural
development, chromatin binding, epithelium development, EMT, KRAS
signaling and extracellular Matrix (Supplemental Fig. 4).
3.4. Differential CTCF binding regulates TET expression in iAs-T cells
Active DNA demethylation occurs mainly through the conversion of
5mC to 5hmC by TET enzyme-mediated oxidation (Hill et al., 2014; Wu
and Zhang, 2017). Since we observed increased global and site-specific
hydroxymethylation in iAs-T cells, we hypothesized there would be an
increase in the expression of TETs. Using qRT-PCR we determined the
relative gene expression of TET1, TET2 and TET3. We found that the
levels increased by about 1.2 to 1.4-fold in iAs-T cells compared to NT
cells (Figs. 6A and 4B). We next tested whether this increase in TET
gene expression correlated with increased TET activity. To answer this
question, we used the 5mC hydroxylase TET activity Assay Kit (Epi-
gentek) to measure the activity of TETs in nuclear extracts obtained
from NT and iAs-T cells. Our results show increase in TET activity in
iAs-T cells compared to NT cells as measured using either the level of
hydroxymethylated product (1.67 vs 0.75 ng/min/mg) (Fig. 6B) or the
Fig. 4. Differential 5hmC levels in the promoter correlate
with changes in gene expression. Validation of promoter
regions that showed (A) Hyper and (C) Hypo 5-hydro-
xymethylation changes in RRHP dataset. Using 5hme-DIP
followed by qRT-PCR five genes were validated with an
increase in 5hmC levels (A) in their promoters in iAs-T cells
and six were validated as having a decrease in 5hmC levels
(C) in their promoters in iAs-T cells. Hydroxymethylation
levels in the promoter correlate with gene expression levels;
genes with an increase in promoter 5hmC levels show in-
creased expression (B) and genes with a decrease in pro-
moter 5hmC levels show decreased expression (D). The *
denotes p < 0.05, error bars represent the SEM.
Fig. 5. Functional Genomic Region analysis of 5mC and 5hmC overlapping loci. Pie
charts show the distribution of loci (7532) at functional genomic regions reveal that both
differential 5mC (measured via MethyMini-Seq) and differential 5hmC (measured via
RRHP) occur. 46.60% of changes were within the gene body; 43.57% were in the inter-
genic region and 9.82% were in the promoter region.
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amount of hydroxylase activity present in the cells (Supplemental
Fig. 5).
To a large degree, the expression of genes is regulated at the level of
transcription initiation mediated by the specific binding of protein
transcription factors (TFs) to short DNA sequence motifs located in gene
promoter regions, the DNA-sequence region upstream of genes. We
asked if iAs could regulate the binding of some key TF to alter gene
expression at the TET promoters. We had previously shown that iAs
inhibition of CTCF binding at the promoters of DNA methyltransferases
(DNMTs) reduced their expression. Interestingly, using the ModEncode
consortium database (UCSC Genome browser), we identified two po-
tential binding sites for CTCF at the promoters of the TET1 and TET2
genes. One of the sites, which is henceforth called the proximal site, is
near the transcription start site (TSS) while the second site is 5 kb and
9 kb upstream of the TSS (henceforth distal site) for TET2 and TET1
respectively (Fig. 6C). We measured the relative occupancy of CTCF in
NT and iAs-T cells at both loci using chromatin immunoprecipitation,
with anti-CTCF antibodies, followed by qRT-PCR (ChIP-qRT-PCR). We
found that the relative occupancy of CTCF at the distal sites of TET1 and
TET2 was increased by at least 2-fold while the occupancy at the
proximal CTCF sites decreased by 2.5- and 5-fold respectively (Fig. 6D).
iAs is known to specifically target CTCF binding to weak CTCF binding
sites (Zhou et al., 2011; Kasowski et al., 2013; Rojas et al., 2015; Rea
et al., 2017). Using in silico analysis, we calculated the strength of these
CTCF binding sites using the CTCFBSDB database: (http://insulatordb.
uthsc.edu/home_new.php) (Bao et al., 2008; Ziebarth et al., 2013). This
database uses motifs from multiple sources to generate Position Weight
Matrices (PWM) and produces log-odds for best fit for sequence against
the background. Using this in silico tool, we found that the distal
binding site of TET1 promoter returned a score of 14.125, while the
proximal binding site returned a score of 6.419. Likewise, the proximal
CTCF binding site at the TET2 promoter the distal region returned a
score of 12.32, while the proximal site returns a score of 8.0. These data
indicate that the distal CTCF binding sites of both TET1 and TET2 are
stronger binding sites than the proximal site.
The results outlined above suggest that these distal CTCF binding
sites may act as enhancer regions for the TET1 and TET2 genes. To test
this hypothesis, we performed ChIP-qRTPCR assays for histone post-
translational modifications (PTMs) known to be associated with pro-
moter (H3K4me3, H3K9ac, H3K27me3) and enhancer regions
(H3K4me1, H3K27ac). First we confirmed the presence of enhancer
associated PTMs at the distal sites while the promoter-associated PTMs
such as H3K9ac and H3K27me3 are low (Fig. 7A and B top panel).
H3K4me3 though typically associated with promoters, can also be
found at enhancers. Nonetheless, compared to promoters, H3K4me3
levels at enhancers are low, and a high ratio of H3K4me1 to H3K4me3
broadly distinguishes enhancers from promoters (Heintzman et al.,
2007; Koch and Andrau, 2011; Djebali et al., 2012). This differential
level of H3K4me3 further confirmed that this site is most likely an
enhancer region (Fig. 7A and B bottom panel). A further comparison
between NT and iAsT cells, showed an increase in the relative occu-
pancy of the enhancer-associated histone PTMs (Supplemental Fig. 6,
left panels) at the TET distal promoter region. For instance, H3K4me1,
H3K4me3 and H3K27ac levels are significantly increased at the distal
region, while the promoter associated-histone PTMs (H3K9ac,
H3K27me3), was decreased slightly or not all (Fig. 7 top panels and
Supplemental Fig. 6, left panels).
At the TET1 proximal promoter region, a decrease in H3Kme1,
H3K4me3, H3K9ac and H3K27me3 was observed while H3K27ac was
not detected when iAs-T was compared to NT cells, (Fig. 7A bottom
panel, Supplemental Fig. 6B, right panel). For the proximal site of TET2,
a similar decrease in H3K4me1, H3K9ac, and H3K27me3 was observed
and again H3k27ac was not detected. Contrary though to TET1 pro-
moter, we observed an increase in H3K4me3 was observed (Fig. 7B
bottom, Supplemental Fig. 6A, right panel). These results suggest that
the increased binding of CTCF to the distal sites is regulatory for TET1
and TET2 expression, and support the hypothesis of these distal CTCF
binding sites maybe potential enhancer regions.
4. Discussion
This study represents the first comprehensive genome-wide analysis
of the differential distribution of 5hmC in response to iAs-mediated
EMT. Most studies investigating changes to epigenome in response to
Fig. 6. CTCF binding is preferentially increased at the distal
binding site of the TET promoter in iAs-T cells directing
increased expression. (A) Graphic representation of qRT-
PCR results showing an increase in gene expression for
TET1 and TET2 in iAs-T cells. (B) Graphic representation of
increase in TET hydroxylase activity in iAs-T cells com-
pared o NT cells. Shown here is Specific Activity as mea-
sured using hydroxylated product produced (ng/min/mg).
Experiments were done in triplicates (C) Cartoon showing
the distal and proximal CTCF binding sites of TET1 (top)
and TET2 (bottom) promoters (D) Graphic representation of
ChIP-qRT-PCR results for CTCF occupancy at TET pro-
moters reveals increased relative occupancy binding at
distal promoter sites and decreased binding at the proximal
CTCF binding sites. The * denotes p < 0.05, error bars
represent the SEM.
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iAs focused on DNA methylation and histone PTMs (Salnikow and
Zhitkovich, 2008; Rea et al., 2016; Eckstein et al., 2017b; Rea et al.,
2017). In this study, we report a global increase in 5-hydro-
xymethylcytosine during iAs-mediated transformation. These results
are in line with several studies showing increased 5hmC levels and
increased TET levels during the process of carcinogenesis (Tsai et al.,
2014; Kao et al., 2016; Tian et al., 2017). These 5hmC genome-wide
changes were not random but found at specific targeted loci. We
identified these 5hmC-targeted loci with changes between NT and iAs-T
cells (Fig. 1, Table 1). Pathway enrichment analyses of genes with
differential 5hmC sites revealed pathways such as cellular commu-
nication, cellular adhesion, and neurogenesis (Fig. 2). Interestingly,
these same pathways were targeted by iAs through DNA reprogram-
ming (Rea et al., 2017). Our findings that the same pathways are tar-
geted by both 5mC and 5hmC are consistent with the idea 5hmC me-
thylation is an important constituent of the DNA demethylation
pathways, contributing to epigenetic plasticity and altered gene ex-
pression in iAs-mediated carcinogenesis.
We next examined the genome-wide distribution of 5mC and 5hmC
(Fig. 3) for two main reasons: 1) demethylation of 5mCs leads to other
products including 5hmCs; and 2) the widely used bisulfite sequencing
is unable to distinguish between methylation and hydroxymethylation,
since both 5mC and 5hmC do not undergo deamination after reacting
with sodium bisulfite. Thus in the RRHP technique, a glucosylation and
a second restriction enzyme digest helps in distinguishing the 5hmC
from 5mCs (Huang et al., 2010). We therefore asked whether the results
from our previous MethylMini-Seq did contain some 5hmC sites. An
overlay of both data showed that there were about 7600 sites that were
identified previously as 5mCs (Fig. 5) that are most likely 5hmCs.
Further analysis also helped to delineate regions previously methylated
that potentially change to a demethylated state with iAs- transforma-
tion (Supplemental Table 3). Furthermore, we illustrate a positive
correlation between 5hmC promoter enrichment and RNA abundance
for several genes (Fig. 4). Not surprisingly, genes with low promoter
5hmC enrichment are least expressed, while genes with high 5hmC at
the promoter are highly expressed. This observation is in agreement
with earlier reports of positive correlation of 5hmC levels with pro-
moter gene expression (Colquitt et al., 2013; Tsai et al., 2014;
Skvortsova et al., 2017). We also observed low 5hmC levels within high
CpG regions (only 16.25% of our dataset), which is in line with previous
studies (Booth et al., 2012; Putiri et al., 2014). One limitation, however
of the RRHP analysis, is that it relies on MspI digest, thus only 5hmC
sites within a CCGG context will be read (Petterson et al., 2014)
This study also reveals a dynamic interplay between TET expression,
CTCF and different chromatin marks (Fig. 6). The simplest explanation
for this observation is that CTCF binding inhibition will inhibit gene
expression of TET genes. After investigating the CTCF occupancy at the
proximal promoter region of the TETs we observed a decrease in the
occupancy at TET1 and TET2 (Fig. 6D). Based on our previous studies,
this decrease in CTCF occupancy should lead to a decrease in gene
expression as we had seen with at the promoters of DNMTs (Rea et al.,
2017). However, the expression of TET genes was increased in iAs-T
Fig. 7. Changes in enhancer-associated histone PTMs at the TET promoter suggest en-
hancer activity of the distal CTCF binding site. Distal Region (top panel) of the TET1 (A)
and TET2 (B) promoters, have elevated enhancer-associated marks (H3k4me1 and
H3k27ac). The proximal promoter regions (A, B bottom panel) show decreased levels of
promoter-associated modifications, however a decrease in the repressive H3K27me3 is
observed. The * denotes p < 0.05, error bars represent the SEM.
Fig. 8. Model for CTCF binding at TET promoters during iAs exposure. In NT cells (Top),
CTCF has occupancy at both distal and proximal binding sites, and TET gene expression
occurs normally. In iAs-T cells (Bottom), depletion of CTCF at the weaker proximal
binding site is associated with an increased binding of CTCF at the stronger CTCF distal
binding site, thus driving increased gene expression at the TET genes. CTCF is a chromatin
architectural protein that forms both short-distance and long-distance loops, bringing
regulatory elements that are often separated by considerable distances. In this figure, we
depict CTCF control of transcription at the TET gene through interactions between en-
hancer region and promoter regions in a three-dimensional nuclear space (Right). To il-
lustrate this, the figure depicts regulatory elements at the TET locus and the CTCF, histone
modifications within these regions.
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cells as well as an increase in the hydroxylase activity (Fig. 6A and B).
Further analyses of the promoter of the TET genes, showed a second
CTCF binding site ~6 to 10 kb upstream of the TSSs (distal site).
Analysis of the relative occupancy of CTCF at these distal sites, showed
an increase in CTCF binding in iAs-T cells. CTCF binds DNA sequence
motifs with specific sequences that influence the strength of CTCF
binding (Nakahashi et al., 2013). Due to this differential binding, we
analyzed the strength of these CTCF binding sites. Thus, using
CTCFBSDB, we determined that the proximal binding site had a motif
weak for CTCF-binding while the motif found at the distal site is a
strong binder. Taken together, these results suggest that iAs blocks
CTCF binding to the weaker target sites, and thus to promote the ob-
served increase in gene expression, the block at the proximal weaker
site must be compensated by increased binding at a stronger binding
site.
CTCF is known to act in several ways to regulate gene expression. It
can act as a transcriptional activator, repressor and insulator, or it can
pause transcription. CTCF is also an architectural protein creating short-
range and long-range loops. In forming short-range loops, CTCF links
promoters to transcription start sites, while in its formation of long-
range loops, CTCF links enhancers to promoters; also acting as an in-
sulator, creating boundaries between topologically associated domains
(TADs). Our data suggest that the binding of CTCF to the stronger site
might loop the regulatory region to the promoter region, to drive TET
expression. To test this idea that the stronger binding site is an en-
hancer, we analyzed enhancer-associated histone PTMs. At both the
TET1 and TET2 distal promoter regions we detected H3K4me1 and
H3K27ac, as well as H3K4me3. Interestingly in iAs-T cells there was an
increase in occupancy of these marks (Fig. 7 top). This finding seems to
suggest that in NT cells, the occupancy of enhancer-associated histone
PTMs, and CTCF binding at the proximal site, drive a ‘normal’ TET
expression. On the otherhand, in iAs-T, because of the reduction of
positive marks (specifically, CTCF binding at the proximal sites), a
compensatory mechanism is occurring, promoting increased CTCF
binding to the distal site to enhance TET expression (Fig. 8).
An understanding of the differential binding of CTCF to target sites
is probably more complicated than the simple model we depict in Fig. 8.
CTCF is known to bind with associated complexes such as condensin
and BORIS (Pugacheva et al., 2010; Nakahashi et al., 2013; Ali et al.,
2016). It is possible that some of these complexes make CTCF an in-
sulator, activator or repressor and that some of these complexes aid in
stronger CTCF binding to the distal site. However, a clear mechanistic
insight into selective inhibition of CTCF by iAs requires a detailed
genome-wide functional analysis of CTCF binding in iAs-T cells. Future
studies will help delineate such selectivity. Interestingly, other heavy
metals have also been shown to inhibit CTCF binding at weaker binding
sites (Jose et al., 2014). Whether this is a mechanism for all heavy
metals remains still to be determined.
In conclusion, this study together with our previous methylation
studies (Rea et al., 2017), demonstrates that selective inhibition of
CTCF binding, regulates epigenomic reprogramming to drive specific
gene expression profiles. And since CTCF insulates TADs and controls
proper genomic architecture and chromosome folding, our studies may
provide a mechanistic insight into the rules governing mammalian
genome organization. Disruptions of these rules may have profound
implications in understanding disease pathogenesis.
Conflict of interest statement
The authors state no conflicts of interest pertaining to this work.
Acknowledgements
We would like to thank the Markey Cancer Center's Research
Communications Office for manuscript editing and assistance with
graphic design (P30 CA177558). GEO accession numbers for Methyl-
MiniSeq data is GSE85012 and RRHP data is GSE103626 this work was
supported by NSF grant MCB 1517986 to YFN-M, NIEHS grant R01-
ES024478, TG was supported by NIEHSR25ES027864 to the SURES
program at UK, and NIH T32 grant 165990 to MR, through Markey
Cancer Center at University of Kentucky.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.taap.2017.11.015.
References
Ali, T., Renkawitz, R., Bartkuhn, M., 2016. Insulators and domains of gene expression.
Curr. Opin. Genet. Dev. 37, 17–26.
Arita, A., Costa, M., 2009. Epigenetics in metal carcinogenesis: nickel, arsenic, chromium
and cadmium. Metallomics 1, 222–228.
Ashktorab, H., Daremipouran, M., Goel, A., Varma, S., Leavitt, R., Sun, X., Brim, H., 2014.
DNA methylome profiling identifies novel methylated genes in African American
patients with colorectal neoplasia. Epigenetics 9, 503–512.
Bachman, M., Uribe-Lewis, S., Yang, X., Williams, M., Murrell, A., Balasubramanian, S.,
2014. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat.
Chem. 6.
Ball, M.P., Li, J.B., Gao, Y., Lee, J.H., LeProust, E.M., Park, I.H., Xie, B., Daley, G.Q.,
Church, G.M., 2009. Targeted and genome-scale strategies reveal gene-body methy-
lation signatures in human cells. Nat. Biotechnol. 27.
Bao, L., Zhou, M., Cui, Y., 2008. CTCFBSDB: a CTCF-binding site database for char-
acterization of vertebrate genomic insulators. Nucleic Acids Res. 36, D83–D87.
Berman, B.P., Weisenberger, D.J., Aman, J.F., 2012. Regions of focal DNA hypermethy-
lation and long-range hypomethylation in colorectal cancer coincide with nuclear
lamina-associated domains. Nat. Genet. 44, 40–46.
Bird, A., 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21.
Booth, M.J., Branco, M.R., Ficz, G., Oxley, D., Krueger, F., Reik, W., Balasubramanian, S.,
2012. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at
single-base resolution. Science 336.
Chen, H.-F., Wu, K.-J., 2016. Epigenetics, TET proteins, and hypoxia in epithelial-me-
senchymal transition and tumorigenesis. Biomedicine 6, 1–8.
Chen, M.L., Shen, F., Huang, W., 2013. Quantification of 5-methylcytosine and 5-hy-
droxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by ca-
pillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spec-
trometry. Clin. Chem. 59, 824–832.
Chen, K., Zhang, J., Guo, Z., Ma, Q., Xu, Z., Zhou, Y., Xu, Z., Li, Z., Liu, Y., Ye, X., Li, X.,
Yuan, B., Ke, Y., He, C., Zhou, L., Liu, J., Ci, W., 2016. Loss of 5-hydro-
xymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res.
26, 103–118.
Cheng, T.-F., Choudhuri, S., Muldoon-Jacobs, K., 2012. Epigenetic targets of some tox-
icologically relevant metals: a review of the literature. JAT 32, 643–653.
Colquitt, B.M., Allen, W.E., Barnea, G., Lomvardas, S., 2013. Alteration of genic 5-hy-
droxymethylcytosine patterning in olfactory neurons correlates with changes in gene
expression and cell identity. Proc. Natl. Acad. Sci. 110, 14682–14687.
Cortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., 2011. Thymine DNA
glycosylase is essential for active DNA demethylation by linked deamination-base
excision repair. Cell 146.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A.M., Tanzer, A.,
Lagarde, J., Lin, W., Schlesinger, F., Xue, C., Marinov, G.K., Khatun, J., Williams,
B.A., Zaleski, C., Rozowsky, J., Röder, M., Kokocinski, F., Abdelhamid, R.F., Alioto,
T., Antoshechkin, I., Baer, M.T., Bar, N.S., Batut, P., Bell, K., Bell, I., Chakrabortty, S.,
Chen, X., Chrast, J., Curado, J., Derrien, T., Drenkow, J., Dumais, E., Dumais, J.,
Duttagupta, R., Falconnet, E., Fastuca, M., Fejes-Toth, K., Ferreira, P., Foissac, S.,
Fullwood, M.J., Gao, H., Gonzalez, D., Gordon, A., Gunawardena, H., Howald, C.,
Jha, S., Johnson, R., Kapranov, P., King, B., Kingswood, C., Luo, O.J., Park, E.,
Persaud, K., Preall, J.B., Ribeca, P., Risk, B., Robyr, D., Sammeth, M., Schaffer, L.,
See, L.-H., Shahab, A., Skancke, J., Suzuki, A.M., Takahashi, H., Tilgner, H., Trout, D.,
Walters, N., Wang, H., Wrobel, J., Yu, Y., Ruan, X., Hayashizaki, Y., Harrow, J.,
Gerstein, M., Hubbard, T., Reymond, A., Antonarakis, S.E., Hannon, G., Giddings,
M.C., Ruan, Y., Wold, B., Carninci, P., Guigó, R., Gingeras, T.R., 2012. Landscape of
transcription in human cells. Nature 489, 101–108.
Eckstein, M., Eleazer, R., Rea, M., Fondufe-Mittendorf, Y., 2017a. Epigenomic repro-
gramming in inorganic arsenic-mediated gene expression patterns during carcino-
genesis. Rev. Environ. Health 32, 93–103.
Eckstein, M., Rea, M., Fondufe-Mittendorf, Y.N., 2017b. Transient and permanent
changes in DNA methylation patterns in inorganic arsenic-mediated epithelial-to-
mesenchymal transition. Toxicol. Appl. Pharmacol.
Feng, S., Cokus, S.J., Zhang, X., Chen, P.-Y., Bostick, M., Goll, M.G., Hetzel, J., Jain, J.,
Strauss, S.H., Halpern, M.E., Ukomadu, C., Sadler, K.C., Pradhan, S., Pellegrini, M.,
Jacobsen, S.E., 2010. Conservation and divergence of methylation patterning in
plants and animals. Proc. Natl. Acad. Sci. U. S. A. 107, 8689–8694.
Globisch, D., Munzel, M., Muller, M., Michalakis, S., Wagner, M., Koch, S., Bruckl, T., Biel,
M., Carell, T., 2010. Tissue distribution of 5-hydroxymethylcytosine and search for
active demethylation intermediates. PLoS One 5.
Grosser, C., Wagner, N., Grothaus, K., Horsthemke, B., 2015. Altering TET dioxygenase
levels within physiological range affects DNA methylation dynamics of HEK293 cells.
M. Rea et al. Toxicology and Applied Pharmacology 338 (2018) 124–133
132
Epigenetics 10, 819–833.
Guo, F., Li, X., Liang, D., Li, T., Zhu, P., Guo, H., Wu, X., Wen, L., Gu, T.P., Hu, B., 2014.
Active and passive demethylation of male and female pronuclear DNA in the mam-
malian zygote. Cell Stem Cell 15.
He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., 2011. Tet-mediated formation of 5-
carboxylcytosine and its excision by TDG in mammalian DNA. Science 333.
Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D., 2007. Distinct
and predictive chromatin signatures of transcriptional promoters and enhancers in
the human genome. Nat. Genet. 39.
Herman, J.G., Baylin, S.B., 2003. Gene silencing in cancer in association with promoter
hypermethylation. N. Engl. J. Med. 349, 2042–2054.
Hill, P.W.S., Amouroux, R., Hajkova, P., 2014. DNA demethylation, Tet proteins and 5-
hydroxymethylcytosine in epigenetic reprogramming: an emerging complex story.
Genomics 104, 324–333.
Hon, G.C., Hawkins, R.D., Caballero, O.L., Lo, C., Lister, R., Pelizzola, M., 2012. Global
DNA hypomethylation coupled to repressive chromatin domain formation and gene
silencing in breast cancer. Genome Res. 22.
Hu, X., Zhang, L., Mao, S.Q., Li, Z., Chen, J., Zhang, R.R., 2014. Tet and TDG mediate
DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell
reprogramming. Cell Stem Cell 14.
Huang, C., Ke, Q., Costa, M., Shi, X., 2004. Molecular mechanisms of arsenic carcino-
genesis. Mol. Cell. Biochem. 255, 57–66.
Huang, Y., Pastor, W.A., Shen, Y., Tahiliani, M., Liu, D.R., Rao, A., 2010. The behaviour of
5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 5, e8888.
IARC, 2004. Some drinking-water disinfectants and contaminants, including arsenic.
IARC Monogr. Eval. Carcinog. Risks Hum. 84, 39–267.
IARC, 2012. Cadmium and Cadmium Compounds. IARC Monogr. Eval. Carcinog. Risks
Hum. 121–146.
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., 2011. Tet proteins can
convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333.
Jjingo, D., Conley, A.B., Yi, S.V., Lunyak, V.V., Jordan, K.I., 2012. On the presence and
role of human gene-body DNA methylation. Oncotarget 3, 462–474.
Jones, P.A., 2012. Functions of DNA methylation: islands, start sites, gene bodies and
beyond. Nat. Rev. Genet. 13, 484–492.
Jones, P.A., Baylin, S.B., 2002. The fundamental role of epigenetic events in cancer. Nat.
Rev. Genet. 3, 415–428.
Jose, C.C., Xu, B., Jagannathan, L., Trac, C., Mallela, R.K., Hattori, T., Lai, D., Koide, S.,
Schones, D.E., Cuddapah, S., 2014. Epigenetic dysregulation by nickel through re-
pressive chromatin domain disruption. Proc. Natl. Acad. Sci. 111, 14631–14636.
Kamburov, A., Pentchev, K., Galicka, H., Wierling, C., Lehrach, H., Herwig, R., 2011.
ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res.
39, D712–D717.
Kamburov, A., Stelzl, U., Lehrach, H., Herwig, R., 2013. The ConsensusPathDB interaction
database: 2013 update. Nucleic Acids Res. 41, D793–D800.
Kao, S.-H., Wu, K.-J., Lee, W.-H., 2016. Hypoxia, Epithelial-Mmesenchymal Transition,
and TET-Mediated Epigenetic Changes. J. Clin. Med. 5, 24.
Kasowski, M., Kyriazopoulou-Panagiotopoulou, S., Grubert, F., Zaugg, J.B., Kundaje, A.,
Liu, Y., Boyle, A.P., Zhang, Q., Zakharia, F., Spacek, D.V., Li, J., Xie, D., Olarerin-
George, A., Steinmetz, L.M., Hogenesch, J.B., Kellis, M., Batzoglou, S., Snyder, M.,
2013. Extensive variation in chromatin states across humans. Science 342, 750–752.
Khalid, O., Kim, J.J., Kim, H.-S., Hoang, M., Tu, T.G., Elie, O., Lee, C., Vu, C., Horvath, S.,
Spigelman, I., Kim, Y., 2014. Gene expression signatures affected by alcohol-induced
DNA methylomic deregulation in human embryonic stem cells. Stem Cell Res. 12,
791–806.
Kinoshita, T., Miura, A., Choi, Y., Kinoshita, Y., Cao, X., Jacobsen, S.E., Fischer, R.L.,
Kakutani, T., 2004. One-way control of FWA imprinting in ArabidopsisEndosperm by
DNA methylation. Science 303, 521.
Koch, F., Andrau, J.-C., 2011. Initiating RNA polymerase II and TIPs as hallmarks of
enhancer activity and tissue-specificity. Transcription 2, 263–268.
Kohli, R.M., Zhang, Y., 2013. TET enzymes, TDG and the dynamics of DNA demethyla-
tion. Nature 502, 472–479.
Kubo, N., Toh, H., Shirane, K., Shirakawa, T., Kobayashi, H., Sato, T., Sone, H., Sato, Y.,
Tomizawa, S.-i., Tsurusaki, Y., Shibata, H., Saitsu, H., Suzuki, Y., Matsumoto, N.,
Suyama, M., Kono, T., Ohbo, K., Sasaki, H., 2015. DNA methylation and gene ex-
pression dynamics during spermatogonial stem cell differentiation in the early
postnatal mouse testis. BMC Genomics 16, 624.
Mayer, W., Niveleau, A., Walter, J., Fundele, R., Haaf, T., 2000. Demethylation of the
zygotic paternal genome. Nature 403.
Miao, Z., Wu, L., Lu, M., Meng, X., Gao, B., Qiao, X., Zhang, W., Xue, D., 2015. Analysis of
the transcriptional regulation of cancer-related genes by aberrant DNA methylation
of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis
caused by arsenic. Oncotarget.
Nakahashi, H., Kieffer Kwon, K.-R., Resch, W., Vian, L., Dose, M., Stavreva, D., Hakim, O.,
Pruett, N., Nelson, S., Yamane, A., Qian, J., Dubois, W., Welsh, S., Phair, R.D., Pugh,
B.F., Lobanenkov, V., Hager, G.L., Casellas, R., 2013. A genome-wide map of CTCF
multivalency redefines the CTCF code. Cell Rep. 3, 1678–1689.
Nestor, C.E., Ottaviano, R., Reddington, J., Sproul, D., Reinhardt, D., Dunican, D., Katz,
E., Dixon, J.M., Harrison, D.J., Meehan, R.R., 2012. Tissue type is a major modifier of
the 5-hydroxymethylcytosine content of human genes. Genome Res. 22, 467–477.
Okano, M., Bell, D.W., Haber, D.A., Li, E., 1999. DNA methyltransferases Dnmt3a and
Dnmt3b are essential for de novo methylation and mammalian development. Cell 99,
247–257.
Petterson, A., Chung, T.H., Tan, D., Sun, X., Jia, X.-Y., 2014. RRHP: a tag-based approach
for 5-hydroxymethylcytosine mapping at single-site resolution. Genome Biol. 15,
1–13.
Pugacheva, E.M., Suzuki, T., Pack, S.D., Kosaka-Suzuki, N., Yoon, J., Vostrov, A.A., 2010.
The structural complexity of the human BORIS gene in gametogenesis and cancer.
PLoS One 5.
Putiri, E.L., Tiedemann, R.L., Thompson, J.J., Liu, C., Ho, T., Choi, J.H., 2014. Distinct
and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the
TET proteins in human cancer cells. Genome Biol. 15.
Rea, M., Zheng, W., Chen, M., Braud, C., Bhangu, D., Rognan, T.N., Xiao, W., 2012.
Histone H1 affects gene imprinting and DNA methylation in Arabidopsis. Plant J. 71,
776–786.
Rea, M., Jiang, T., Eleazer, R., Eckstein, M., Marshall, A.G., Fondufe-Mittendorf, Y.N.,
2016. Quantitative mass spectrometry reveals changes in histone H2B variants as
cells undergo inorganic arsenic-mediated cellular transformation. Mol. Cell.
Proteomics 15, 2411–2422.
Rea, M., Eckstein, M., Eleazer, R., Smith, C., Fondufe-Mittendorf, Y.N., 2017. Genome-
wide DNA methylation reprogramming in response to inorganic arsenic links in-
hibition of CTCF binding, DNMT expression and cellular transformation. Sci. Rep. 7,
41474.
Ren, X., McHale, C.M., Skibola, C.F., Smith, A.H., Smith, M.T., Zhang, L., 2011. An
emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis.
Environ. Health Perspect. 119, 11–19.
Riedmann, C., Ma, Y., Melikishvili, M., Godfrey, S., Zhang, Z., Chen, K., Rouchka, E.C.,
Fondufe-Mittendorf, Y.N., 2015. Inorganic arsenic-induced cellular transformation is
coupled with genome wide changes in chromatin structure, transcriptome and spli-
cing patterns. BMC Genomics 16, 212.
Rojas, D., Rager, J.E., Smeester, L., Bailey, K.A., Drobna, Z., Rubio-Andrade, M., Styblo,
M., Garcia-Vargas, G., Fry, R.C., 2015. Prenatal arsenic exposure and the epigenome:
identifying sites of 5-methylcytosine alterations that predict functional changes in
gene expression in newborn cord blood and subsequent birth outcomes. Toxicol. Sci.
143, 97–106.
Salnikow, K., Zhitkovich, A., 2008. Genetic and epigenetic mechanisms in metal carci-
nogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem. Res. Toxicol.
21, 28–44.
Skvortsova, K., Zotenko, E., Luu, P.-L., Gould, C.M., Nair, S.S., Clark, S.J., Stirzaker, C.,
2017. Comprehensive evaluation of genome-wide 5-hydroxymethylcytosine profiling
approaches in human DNA. Epigenetics Chromatin 10, 16.
Song, C.-X., He, C., 2012. Balance of DNA methylation and demethylation in cancer de-
velopment. Genome Biol. 13, 1–3.
Spandidos, A., Wang, X., Wang, H., Dragnev, S., Thurber, T., Seed, B., 2008. A compre-
hensive collection of experimentally validated primers for polymerase chain reaction
quantitation of murine transcript abundance. BMC Genomics 9, 633.
Spandidos, A., Wang, X., Wang, H., Seed, B., 2010. PrimerBank: a resource of human and
mouse PCR primer pairs for gene expression detection and quantification. Nucleic
Acids Res. 38, D792–D799.
Tekpli, X., Urbanucci, A., Hashim, A., Vågbø, C.B., Lyle, R., Kringen, M.K., Staff, A.C.,
Dybedal, I., Mills, I.G., Klungland, A., Staerk, J., 2016. Changes of 5-hydro-
xymethylcytosine distribution during myeloid and lymphoid differentiation of
CD34+ cells. Epigenetics Chromatin 9, 1–13.
Tian, Y., Pan, F., Sun, X., Gan, M., Lin, A., Zhang, D., Zhu, Y., Lai, M., 2017. Association of
TET1 expression with colorectal cancer progression. Scand. J. Gastroenterol. 52,
312–320.
Treas, J.N., Tyagi, T., Singh, K.P., 2012. Effects of chronic exposure to arsenic and es-
trogen on epigenetic regulatory genes expression and epigenetic code in human
prostate epithelial cells. PLoS One 7.
Tsai, Y.-P., Chen, H.-F., Chen, S.-Y., Cheng, W.-C., Wang, H.-W., Shen, Z.-J., Song, C.,
Teng, S.-C., He, C., Wu, K.-J., 2014. TET1 regulates hypoxia-induced epithelial-me-
senchymal transition by acting as a co-activator. Genome Biol. 15, 513.
Wu, X., Zhang, Y., 2017. TET-mediated active DNA demethylation: mechanism, function
and beyond. Nat. Rev. Genet. 18 (9), 517–534 (advance online publication).
Xiao, W., Custard, K.D., Brown, R.C., Lemmon, B.E., Harada, J.J., Goldberg, R.B., Fischer,
R.L., 2006. DNA methylation is critical for Arabidopsis embryogenesis and seed
viability. Plant Cell 18, 805–814.
Ye, C., Li, L., 2014. 5-hydroxymethylcytosine. Cancer Biol. Ther. 15, 10–15.
Yu, M., Hon, G.C., Szulwach, K.E., Song, C.X., Zhang, L., Kim, A., Li, X., Dai, Q., Shen, Y.,
Park, B., 2012. Base-resolution analysis of 5-hydroxymethylcytosine in the mam-
malian genome. Cell 149.
Zhang, P., Huang, B., Xu, X., Sessa, W.C., 2013. Ten-eleven translocation (Tet) and thy-
mine DNA glycosylase (TDG), components of the demethylation pathway, are direct
targets of miRNA-29a. Biochem. Biophys. Res. Commun. 437.
Zhou, X., Sun, X., Cooper, K.L., Wang, F., Liu, K.J., Hudson, L.G., 2011. Arsenite interacts
selectively with zinc finger proteins containing C3H1 or C4 motifs. J. Biol. Chem.
286, 22855–22863.
Ziebarth, J.D., Bhattacharya, A., Cui, Y., 2013. CTCFBSDB 2.0: a database for CTCF-
binding sites and genome organization. Nucleic Acids Res. 41, D188–D194.
M. Rea et al. Toxicology and Applied Pharmacology 338 (2018) 124–133
133
